EPI 506

Drug Profile

EPI 506

Alternative Names: EPI-506; Pro-drug of EPI-002

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator ESSA Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 14 Dec 2016 United Kingdom and France approves IND application for phase II trial of EPI 506 in Prostate cancer
  • 14 Dec 2016 ESSA Pharma plans a phase II trial for Prostate cancer (Hormone refractory, Second-line therapy or greater) in USA and Canada
  • 01 Dec 2015 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater) in Canada (PO) (NCT02606123)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top